Survival outcome of different treatment sequences in patients with locally advanced and metastatic pancreatic cancer

Survival outcome of different treatment sequences in patients with locally advanced and metastatic pancreatic cancer

Abstract Background Despite some therapeutic advances, improvement in survival rates of unresectable and/or metastatic pancreatic ductal adenocarcinoma (PDAC) has been minimal over recent decade. We aimed to evaluate the impact of different treatment sequences on clinical outcomes of advanced PDAC a...

Full description

Bibliographic Details
Main Authors:	Mengjiao Fan, Guochao Deng, Yue Ma, Haiyan Si, Zhikuan Wang, Guanghai Dai
Format:	Article
Language:	English
Published:	BMC 2024-01-01
Series:	BMC Cancer
Subjects:	Pancreatic ductal adenocarcinoma Treatment landscape Treatment patterns Treatment sequences New chemotherapy regimens Irinotecan
Online Access:	https://doi.org/10.1186/s12885-024-11823-8

Similar Items

Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club
by: Katarzyna Winter, et al.
Published: (2019-03-01)

Multimodal Approaches to Patient Selection for Pancreas Cancer Surgery
by: Hala Muaddi, et al.
Published: (2024-04-01)

A case of pathological complete response with liposomal irinotecan + 5-FU/LV for unresectable locally advanced pancreatic cancer
by: Koji Kikuchi, et al.
Published: (2022-10-01)

Impact and optimal timing of local therapy addition in borderline resectable or locally advanced pancreatic cancer after FOLFIRINOX chemotherapy
by: Kangpyo Kim, et al.
Published: (2024-03-01)

Ferroptosis: New Strategies and Ideas for the Treatment of Pancreatic Ductal Adenocarcinoma
by: Chengru Yang, et al.
Published: (2024-01-01)

Sequential Treatment of Metastatic Adenocarcinoma of the Pancreatic Duct with Liver Metastasis Following the NAPOLI-1 Study Protocol with nal-Irinotecan plus 5-FU in the Second Line
by: Dilara Akhoundova Sanoyan, et al.
Published: (2020-02-01)

Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions
by: Yiyin Zhang, et al.
Published: (2018-01-01)

Metastatic Pancreatic Cancer: Current Treatment Options for Swiss Patients
by: Sara De Dosso, et al.
Published: (2021-06-01)

Genetic Signature of Human Pancreatic Cancer and Personalized Targeting
by: Stephan J. Reshkin, et al.
Published: (2024-03-01)

Role of CA 19.9 in the Management of Resectable Pancreatic Cancer: State of the Art and Future Perspectives
by: Alessandro Coppola, et al.
Published: (2022-08-01)

The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies
by: Marwa Elsayed, et al.
Published: (2021-04-01)

Neoadjuvant Treatment in Resectable Pancreatic Cancer. Is It Time for Pushing on It?
by: Marco Vivarelli, et al.
Published: (2022-05-01)

Skeletal Muscle Index Changes on Locoregional Treatment Application After FOLFIRINOX and Survival in Pancreatic Cancer
by: Ji Hye Min, et al.
Published: (2025-02-01)

Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma
by: Shih-Hung Yang, et al.
Published: (2022-04-01)

Additional adjuvant radiotherapy improves survival at 1 year after surgical treatment for pancreatic cancer patients with T4, N2 disease, positive resection margin, and receiving adjuvant chemotherapy
by: Lili Wu, et al.
Published: (2023-07-01)

ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenocarcinoma. An Australasian Gastro-Intestinal Trials Group (AGITG) trial✰
by: J. Lee, et al.
Published: (2023-10-01)

Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?
by: Bolun Jiang, et al.
Published: (2020-10-01)

Dynamic serum alkaline phosphatase is an indicator of overall survival in pancreatic cancer
by: Yuanyuan Xiao, et al.
Published: (2019-08-01)

Adjuvant 5‐fluorouracil and portal vein infusion chemotherapy followed by gemcitabine for pancreatic cancer
by: Minoru Kitago, et al.
Published: (2024-07-01)

The Emerging Role of Microbiota and Microbiome in Pancreatic Ductal Adenocarcinoma
by: Sona Ciernikova, et al.
Published: (2020-12-01)

Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer
by: Ryoji Takada, et al.
Published: (2023-07-01)

Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma
by: Kenneth H. Yu, et al.
Published: (2023-04-01)

Disparities in Pancreatic Ductal Adenocarcinoma—The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes
by: Andrea N. Riner, et al.
Published: (2020-06-01)

The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor
by: Saber Amin, et al.
Published: (2020-09-01)

Survival Analysis of 4 Different Age Groups of Pancreatic Ductal Adenocarcinoma After Radical Resection From Retrospective Multi‐Center Analysis (YPB‐003)
by: Hiroto Matsui, et al.
Published: (2025-02-01)

Identification of FEZ2 as a potential oncogene in pancreatic ductal adenocarcinoma
by: Chaozhi Yang, et al.
Published: (2022-01-01)

Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study
by: Amol Gupta, et al.
Published: (2023-08-01)

Fighting Pancreatic Cancer with a Vaccine-Based Winning Combination: Hope or Reality?
by: Silvia Brugiapaglia, et al.
Published: (2024-09-01)

Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy
by: Sumit Sahni, et al.
Published: (2023-09-01)

Long-term survival with repeat resection for lung oligometastasis from pancreatic ductal adenocarcinoma: a case report
by: Ryota Matsuki, et al.
Published: (2018-03-01)

Metabolic Adaptation during nab-Paclitaxel Resistance in Pancreatic Cancer Cell Lines
by: Lukas M. Braun, et al.
Published: (2020-05-01)

Pancreatic ductal adenocarcinoma arising from the pancreatic parenchyma compressed by a huge pancreatic lipoma: a case report
by: Seiji Nakahara, et al.
Published: (2023-08-01)

Pancreatic tail cancer in the setting of pancreatitis with a review of the literature: A case report
by: Shinji Rho, et al.
Published: (2023-10-01)

Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?
by: Violette Fossaert, et al.
Published: (2022-10-01)

Clinical features and images of malignant lymphoma localized in the pancreatic head to differentiate from pancreatic ductal adenocarcinoma: a case series study
by: Naohiro Kato, et al.
Published: (2023-05-01)

Tumor-Infiltrating Immune Cell Signature Predicts the Prognosis and Chemosensitivity of Patients With Pancreatic Ductal Adenocarcinoma
by: Yuzhen Gao, et al.
Published: (2020-09-01)

Study protocol of the METAPANC trial - intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatment versus chemotherapy alone: a randomized controlled trial
by: Michael Ghadimi, et al.
Published: (2025-02-01)

Establishment and validation of a prognostic signature for pancreatic ductal adenocarcinoma based on lactate metabolism-related genes
by: Xin Huang, et al.
Published: (2023-06-01)

Monitoring of circulating tumour DNA in advanced pancreatic ductal adenocarcinoma predicts clinical outcome and reveals disease progression earlier than radiological imaging
by: Karin Hestnes Edland, et al.
Published: (2023-09-01)

Realising the therapeutic potential of the human microbiota in metastatic pancreatic ductal adenocarcinoma
by: James M. Halle-Smith, et al.
Published: (2023-12-01)